They also demonstrated the expected myoanabolic activity in LA at 30 mg/kg to be greater than intact control, but less than DHT at 10 mg/kg. Kaken built their compounds around the bicyclic THQ and tricyclic 3,4-cyclopentano THQ scaffolds (Figure 4) and disclosed structure-activity relationships for the binding to AR based on THQ substitution patterns (US Patent 6,777,427 Miyakawa et al., 2004a). LGD-3303 is a hypermyoanabolic and osteoanabolic agonist in rats with an LA Emax of 220%, but also supports 100% of prostate at this dose. A third compound in preparation for clinical testing, LGD-3303 (structure not disclosed), was recently reported at the 2007 American Society for Bone and Mineral Research (ASBMR) Meeting (unpublished data). A recent publication characterized the pre-clinical osteo- and myoanabolic properties of LGD2941 in rats (15) Martinborough et al., 2007; Wang et al., 2006. LGD2226 (14) demonstrated myoanabolism weaker than testosterone and osteoanabolism which was shown to increase bone mineral density (BMD), improve bone structure and strength, and positively affect bone biomarkers. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data). The AR binds to the ARE on the promoter of androgen responsive genes, leading to the recruitment of coactivators (p160s, CBP, TRAP, ARAs) and general transcription factors (GTF), leading to gene transcription. The receptor is basally phosphorylated in the absence of hormone and hormone binding increases the phosphorylation status of the receptor (P). This facilitates a series of conformational changes, with helices 3 and 5 serving as the key interfaces following the dissociation of corepressor complexes, leading to nuclear entry and binding to AREs in the promoter of androgen-responsive genes. In addition to the ligand binding function, the LBD also contains a second activation function (AF-2) that is important for the ligand-dependent activation of the receptor. The LBD of the receptor is responsible for ligand binding and is not well conserved among the receptors. Some prostate cancer-specific mutations in the hinge suggest that the hinge region plays a role in DNA binding and coactivator recruitment Tilley et al., 1996; Wang and Uchida, 1997. The hinge region that lies between the DBD and the ligand binding domain (LBD) is a lysine-rich region that is important for the nuclear localization signal (NLS) of the receptor Gao et al., 1996; Ylikomi et al., 1992. Muscle weakness can be a potential side effect when liver function is compromised, highlighting the importance of regular monitoring. Some studies suggest it may elevate liver enzymes, indicating possible liver stress or damage, especially with high doses or prolonged use. Research involving male rats has shown promising results regarding muscle retention and its ability to improve physical function. Users should approach these substances cautiously, conduct thorough research, and consider regular health monitoring throughout the cycle. Users report increased stamina, quicker recovery times, and a more defined physique when combining the two compounds. Doses often fall between mg/day for ostarine and mg/day for cardarine, depending on experience level and goals. Cardarine, on the other hand, is a PPARδ receptor agonist that boosts endurance and enhances fat metabolism. Some of the published benzimidazole compounds were characterized as potent and efficacious myoanabolic SARMs. ORX, T, TP, and CaP are abbrevations for orchidectomy, testosterone, testosterone propionate, and prostate cancer, respectively. Figure 5 illustrates how BMS obtained potent and selective SARM activity by simplifying the B-ring to a 5.5 bicyclic hydantoin, which has a hydroxyl substituent properly located to interact with N705 (contrast (25b) and (26)). Compound (20) (30 mg/kg) partially increased VP weight as compared to intact controls (70 mg/100 g vs. 94 mg/100 g), but demonstrated full osteoanabolic activity and hypermyoanabolic activity. S (16) was extensively characterized for its osteoanabolic activity by Hanada et al. Compound (28) was the only molecule that demonstrated full myoanabolic efficacy in the same restorative assay as for (27). Also explored in this work were α, β-unsaturated and saturated cyclic amide variations on the hydantoin theme (not shown) which retained significant affinity and in vitro activity, but demonstrated poor in vivo activity. Moreover, the stereochemistry of the hydroxyl group is very important for binding affinity and in vitro activity. Separately, BMS explained how to convert certain of their antagonists into agonists with SARM activity Sun et al., 2006. Note that some or all of the data presented for (16-24) was derived from the indicated patents. A further investigation is necessary to fully understand ostarine metabolism, especially in regular users, and the toxicological relevance of the potential in vivo production of cyanophenol-sulfate. We suggest ostarine-glucuronide and hydroxybenzonitrile-ostarine-glucuronide (M4) in non-hydrolyzed urine and ostarine and hydroxybenzonitrile-ostarine (M9) in hydrolyzed urine as markers to document ostarine intake in doping. A total of ten metabolites produced by O-glucuronidation, hydroxylation, ether cleavage, dealkylation, and sulfation were identified with consistent results between in vitro and in vivo data. The metabolic profile of ostarine, a SARM doping agent, was investigated with ten-donor-pooled human hepatocyte incubations and urine samples from six ostarine-positive cases.
